569 - Identification of Ampicillin and Vancomycin In Vitro Susceptibility Test Interpretive Criteria for Enterococcus faecalis and Enterococcus faecium

Presenting Author(s)

• 

  Sujata M. Bhavnani, PharmD; MS; FIDSA

  Executive Vice President
  Institute for Clinical Pharmacodynamics
  Schenectady, New York, United States

  Slides

Co-Author(s)

• JH

  Jeffrey P. Hammel, MS

  Director
  Institute for Clinical Pharmacodynamics
  Schenectady, New York, United States
• CR

  Christopher M. Rubino, PharmD

  Executive Vice President
  Institute for Clinical Pharmacodynamics
  Schenectady, New York, United States
• 

  Brian D. VanScoy, B.S.

  Director
  Institute for Clinical Pharmacodynamics
  Schenectady, NY, United States
• MS

  M. Courtney Safir, PharmD

  Institute for Clinical Pharmacodynamics
  Schenectady, New York, United States
• JT

  Jennifer K. Torgersen, Pharm.D.

  Institute for Clinical Pharmacodynamics, Inc.
  Schenectady, New York, United States
• 

  Rodrigo E. Mendes, PhD (he/him/his)

  Director
  Element Iowa City (JMI Laboratories)
  North Liberty, IA, United States
• HS

  Helio Sader
• PA

  Paul G. Ambrose, PharmD; MS; FIDSA

  President
  Institute for Clinical Pharmacodynamics
  Schenectady, New York, United States